SAN MARINO, Calif.--(BUSINESS WIRE)--Viral Genetics, Inc. (Pink Sheets: VRAL) today posted to its website a President’s Letter to Shareholders that reviews the past year and looks ahead to what 2012 holds for the Company. Highlights of the President’s letter, including key updates on the Company’s important cancer study and biofuel testing programs, are below. In particular, in 2011 our Metabolic Disruption technology (MDT) additives successfully produced significant algal oil yield increases in independent testing at larger-scale production environments; and, though later than announced, three of the Company’s most promising pharmaceutical products – its therapies for treatment-resistant cancer with MDT compounds, its treatment of HIV/AIDS with APi1177, and its treatment of Lyme disease with VGV-L – are anticipated to commence or follow up on prior FDA reviews at various times in 2012, including one clinical trial.
